• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
  • About Us
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies

by Elena Iemma | Apr 1, 2024

Identification of immunodominant T cell epitopes induced by natural Zika virus infection

Identification of immunodominant T cell epitopes induced by natural Zika virus infection

by Elena Iemma | Aug 30, 2023

H1N1 G4 swine influenza T cell epitope analysis in swine and human vaccines and circulating strains uncovers potential risk to swine and humans

H1N1 G4 swine influenza T cell epitope analysis in swine and human vaccines and circulating strains uncovers potential risk to swine and humans

by Elena Iemma | Oct 26, 2022

Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy

Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy

by Elena Iemma | Dec 9, 2021

Novel immunogen design elicits increased protection against avian H7N9 influenza that is associated with mobilization of seasonal influenza T cell memory

Novel immunogen design elicits increased protection against avian H7N9 influenza that is associated with mobilization of seasonal influenza T cell memory

by Elena Iemma | Sep 13, 2021

Novel immunogen design elicits increased protection against avian H7N9 influenza that is associated with mobilization of seasonal influenza T cell memory
« Older Entries

Recent Posts

  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.